Business
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of scleroderma and/or systemic sclerosis. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover the use of MN-001 (tipelukast) or MN-002 for treating scleroderma and/or systemic sclerosis and for reducing and/or inhibiting elevated hydroxyproline levels in scleroderma/systemic sclerosis. The allowed claims cover oral administration including liquid and solid dosage forms (tablets or capsules). The allowed claims cover a wide range of doses and a range of different dosing frequencies. Kazuko Matsuda, M.D. Ph. D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “This new patent approval is based on positive results in a systemic sclerosis animal model study conducted previously. We are very pleased to receive notice that this new patent will be granted. We believe this additional patent in Canada could increase the potential value of MN-001.” About MN-001 (tipelukast) MN-001 (tipelukast) is a novel, orally administered, small molecule compound with multiple mechanisms of action which has been in clinical development for the treatment of chronic inflammatory and fibrotic diseases, among others, due to its anti-inflammatory and anti-fibrosis effects. Based on the finding that MN-001 (tipelukast) reduces triglycerides (TG) in the blood from our previous clinical trials, we conducted a Phase 2 clinical trial in patients with hypertriglyceridemia and NASH or NAFLD. Based on the findings from the in-vitro mechanistic study of MN-001 (tipelukast), a subgroup analysis of the Phase 2 clinical trial showed a stronger improvement in lipid profile in the NASH/NAFLD patients with a history of diabetes. Therefore, a new Phase 2 clinical trial was initiated to investigate the effect of MN-001 (tipelukast) in NAFLD patients with type 2 diabetes and hypertriglyceridemia. The molecular mechanism of action of MN-...